iRhythm Technologies (IRTC) recently announced that it had signed an exclusive license agreement with BioIntelliSense, Inc., a continuous health monitoring and clinical intelligence company, to develop and commercialize certain patented technology assets within ambulatory cardiac monitoring (ACM). With the agreement, it is likely to utilize BioIntelliSense's multiparameter sensing technologies to expand the capabilities of its platform. IRTC's management believes that the licensed technology from BioIntelli ...